Company Description

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.

Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.

The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.

Synlogic, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	1
CEO	Mary Dooley

Contact Details

Address: PO Box 30 Winchester, Massachusetts 01890 United States
Phone	617 659 2802
Website	synlogictx.com

Stock Details

Ticker Symbol	SYBX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001527599
CUSIP Number	87166L100
ISIN Number	US87166L2097
Employer ID	26-1824804
SIC Code	2834

Key Executives

Name	Position
Mary Beth Dooley	Principal Executive Officer and Principal Financial Officer
Dr. Timothy K. Lu M.D., Ph.D.	Co-Founder and Member of Scientific Advisory Board
Dr. James J. Collins Ph.D.	Co-Founder and Member of Scientific Advisory Board
Dr. Jose-Carlos Gutierrez-Ramos Ph.D.	Advisor

Latest SEC Filings

Date	Type	Title
Nov 13, 2025	10-Q	Quarterly Report
Nov 13, 2025	SCHEDULE 13G/A	Filing
Nov 12, 2025	ARS	Filing
Nov 12, 2025	DEF 14A	Other definitive proxy statements
Aug 20, 2025	EFFECT	Notice of Effectiveness
Aug 15, 2025	S-3/A	[Amend] Registration statement under Securities Act of 1933
Aug 13, 2025	UPLOAD	Filing
Aug 8, 2025	S-3	Registration statement under Securities Act of 1933
Aug 7, 2025	10-Q	Quarterly Report
May 8, 2025	10-Q	Quarterly Report

View All SEC Filings